Astrazeneca (AZN. L) as much as $1.15 billion, Britain's second-biggest drugmaker drive steps, to rebuild its product line by trading decision is to buy the respiratory system drugs expert eye treatment.
Acquisition of privately held companies, to ensure that astrazeneca LABA/from commitment to improve patient compliance and disease control, no steroid drugs is known as a new class of the status of an emerging market for lung cancer treatment.
Some industry analysts think, LABA/from LAMA inhaler will dominate the future treatment of chronic obstructive pulmonary disease (COPD), and this will lead to debilitating breathing difficulties and impact, estimates there are 2.1 million people around the world.
Buy redwood city, based in California, pearl fills a blank in the combination of astrazeneca's breathing, even though it is still behind rivals, including glaxosmithkline (GSK) L) and novartis (NOVN. VX) in the race to develop new type of inhaling drugs.
Astrazeneca PLC said on Monday that the company will pay the $5.6 million initial and up to $4.5 million, if a certain development milestones, as well as sales related pay up to $140 million in further.
The deal is an important part of the new chief executive of Pascal Soriot, who took over last October, British company breathing, bet he has identified as core therapeutic areas.
Astrazeneca's sales and profits drop, because the old drugs lose patent protection, the company desperately needs new products, to replace the previous big sellers, last year lost exclusive, such as antipsychotic drugs, rui kang.
The agreement the second bolt is Soriot acquisitions, in two weeks, after an agreement to buy Omthera pharmaceutical (OMTH. O) $443 million to establish its cardiovascular drugs business as much as possible.
Later in the market
, astrazeneca has a successful existing Symbicort inhalation of respiratory drugs, but risked lost in for a long time not have LABA/from inhaling.
Pearl's leading products, PT003 is in the final stages of the first phase III clinical trials and a fixed dose combination fumaric acid f ROM mott, a long-acting beta - 2 - agonists (LABA) and lung, alkali antagonists (from) a long-term a toadstool.
It also has another product called PT010 this is a triple combination drug, inhaled corticosteroids in combination with the dalai lama and PT003 LABA components. Astrazeneca company said, the triple combination drugs can accelerate to enter phase ii clinical development.
Berenberg bank industry analysts say, PT003 will be late, novartis may get regulatory approval first, LABA/from products of Europe later this year, with GSK is not far behind Europe and the United States market.
Germany boehringer YanGeHan company and forest laboratories (usd) N) work Almirall (ALM. MC), three phase should be complete by the end of the year plan, PT003 ahead of time, make astrazeneca fifth into the potential market.
PT003 also take two times a day, instead of once a day, some of our competitors, but, astrazeneca wish pearl pressure quantitative inhaler device may give its edge.
Berenberg said the attack on the biggest deal in the pearl river may come from the combination of the triple, astrazeneca is probably the second market, second only to GSK.
, the pharmaceutical company, said the acquisition is expected in the third quarter of 2013, astrazeneca PLC's financial guidance this year will not have any effect.
Pearl's supporters, who stand to gain from sales, including CLARUS 05 a.m. venture capital firms, venture capital firms, the leaves grow vc and rapid medical partners.



Other News:
AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 billion
Obama says US, China must develop cyber rules
Congress briefed on US surveillance programs
Brutal witch hunts in PNG being linked to jealousy
Treasury to sell 30 million shares of GM stock
Suicide blast in Kabul kills 14 at Supreme Court
Netflix stock sinks on mixed reviews of 'Arrested'
Obama: Gov't records sweep not targeting Americans